Loading...

David Wofsy, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address533 Parnassus Avenue
San Francisco CA 94117
Phone415-502-2397
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine
    University of California, San Francisco, CA2017Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    American College of Rheumatology2012Master of the American College of Rheumatology
    New York Academy of Medicine2011Paul Klemperer Award and Medal
    Arthritis Foundation2007Lee C. Howley Sr. Prize
    Arthritis Foundation2001Arthritis Hero Award
    American College of Rheumatology1999Edmund L. Dubois Award for Outstanding Research in SLE

    Collapse Overview 
    Collapse Overview
    Dr. Wofsy received his undergraduate degree from Harvard (1968), his MD from the University of California, San Diego (1974), and his medical residency training and rheumatology fellowship training from the University of California, San Francisco. He joined the UCSF faculty in 1980. He currently Professor of Medicine and Microbiology/Immunology at UCSF. Dr. Wofsy also serves as Associate Dean for Admissions for the UCSF School of Medicine. He has served on numerous NIH study sections, and on the Arthritis Advisory Committee of the Food and Drug Administration. Dr. Wofsy is a past-President of the American College of Rheumatology.

    Dr. Wofsy's research program is devoted to the development of novel therapies for autoimmune diseases, particularly systemic lupus erythematosus (SLE). For many years, his research focused on the cellular and molecular mechanisms that lead to autoimmunity in murine models for SLE. These therapies are designed to block pathologic immune responses without damaging the entire immune system. One of the therapies that was pioneered by Dr. Wofsy's group involves the B7 family of molecules on antigen-presenting cells (APC). These molecules play a pivotal role in the generation of T-cell help. Specifically, the interaction of B7 molecules on APC with their ligand (designated CD28) on T cells provides an important signal for T-cell activation. Dr. Wofsy first showed that selective inhibition of the B7-CD28 interaction retards autoimmunity in murine lupus. He subsequently showed that this beneficial effect could be enhanced substantially in two ways: (i) by combining blockade of B7-CD28 with blockade of other receptor-ligand pairs (CD40-CD40L) on the surface of T cells and APC; and (ii) by combining blockade of B7-CD28 with cyclophosphamide therapy. In each case, combination therapy provided a prolonged benefit without sustained generalized immune suppression. This work laid the foundation for translational studies that resulted in FDA approval of a new treatment for rheumatoid arthritis. Dr.Wofsy's current research is focused on establishing whether this therapy can be life-saving in people with kidney disease due to SLE.

    Collapse Research 
    Collapse Research Activities and Funding
    PEARL: Pathway Exploration and Analysis in Renal Lupus
    NIH/NIAMS UH2AR067688Sep 24, 2014 - May 31, 2020
    Role: Principal Investigator
    Autoimmunity Center of Excellence Clinical Research Program
    NIH/NIAID UM1AI110498May 1, 2014 - Apr 30, 2020
    Role: Principal Investigator
    Autoimmunity Center of Excellence
    NIH/NIAID U19AI056388Sep 30, 2003 - Mar 31, 2009
    Role: Principal Investigator
    NEW STRATEGIES FOR USING ANTI-L3T4 TO STUDY MURINE LUPUS
    NIH/NIAID R01AI025578May 1, 1988 - Apr 30, 1991
    Role: Principal Investigator
    MULTIPURPOSE ARTHRITIS AND MUSCULOSKELETAL DISEASES CTR
    NIH/NIAMS P60AR020684Apr 1, 1986 - Dec 31, 2003
    Role: Principal Investigator
    Academic Rheumatology and Clinical Immunology
    NIH/NIAMS T32AR007304Jul 1, 1978 - Jun 30, 1999
    Role: Co-Principal Investigator
    U.C.S.F. MULTIPURPOSE ARTHRITIS CENTER
    NIH P60AM020684Sep 15, 1977 - Dec 31, 1988
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Sep 29, 2006
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020 Aug 14. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. PMID: 32816709.
      View in: PubMed   Mentions:    Fields:    
    2. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2020 Aug 04. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Lim SS, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. PMID: 32755035.
      View in: PubMed   Mentions:    Fields:    
    3. Integrated urine proteomics and renal single-cell genomics identify an IFN-? response gradient in lupus nephritis. JCI Insight. 2020 Jun 18; 5(12). Fava A, Buyon J, Mohan C, Zhang T, Belmont HM, Izmirly P, Clancy R, Trujillo JM, Fine D, Zhang Y, Magder L, Rao DA, Arazi A, Berthier CC, Davidson A, Diamond B, Hacohen N, Wofsy D, Apruzzese W, Raychaudhuri S, Petri M. PMID: 32396533.
      View in: PubMed   Mentions:    Fields:    
    4. A Tale of Two Trials. Arthritis Rheumatol. 2020 Mar 17. Wofsy D. PMID: 32182394.
      View in: PubMed   Mentions:    Fields:    
    5. The Validity of Scores From the New MCAT Exam in Predicting Student Performance: Results From a Multisite Study. Acad Med. 2020 03; 95(3):387-395. Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K. PMID: 31425189.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care Res (Hoboken). 2020 02; 72(2):233-242. Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A. PMID: 31502417.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Georgia Abortion Law and Our Commitment to Patients. Arthritis Rheumatol. 2020 02; 72(2):377-378. Craft JE, Crow MK, Lockshin MD, Salmon JE, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin J, Koopman WJ, Seaman WE, Wofsy D, Sergent JS, Uknis AB, Weinblatt ME. PMID: 31637878.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. Nat Rev Nephrol. 2020 04; 16(4):238-250. Rao DA, Arazi A, Wofsy D, Diamond B. PMID: 31853010.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    9. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019 10 17; 4(20). Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise ES, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA. PMID: 31536480.
      View in: PubMed   Mentions: 5     Fields:    
    10. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 Oct; 20(10):1404. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. PMID: 31409923.
      View in: PubMed   Mentions:    Fields:    
    11. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 09; 71(9):1400-1412. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. PMID: 31385462.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    12. Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract. 2019; 3(2):rkz021. Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P. PMID: 31528843.
      View in: PubMed   Mentions:
    13. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 09; 78(9):1151-1159. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. PMID: 31383717.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    14. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 07; 20(7):902-914. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. PMID: 31209404.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    15. Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools. Acad Med. 2019 03; 94(3):388-395. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P. PMID: 30188370.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 05; 78(5):634-640. Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. PMID: 30692164.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 03; 71(3):431-440. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD. PMID: 30277008.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    18. Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. J Rheumatol. 2019 07; 46(7):721-726. Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M. PMID: 30554156.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools? Acad Med. 2018 08; 93(8):1227-1233. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. PMID: 29561273.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. Acad Med. 2018 07; 93(7):1029-1034. Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P. PMID: 29095170.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. Kidney Int Rep. 2018 Sep; 3(5):1057-1063. Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L. PMID: 30197972.
      View in: PubMed   Mentions:
    22. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889. Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. PMID: 29563108.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    23. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care Res (Hoboken). 2018 04; 70(4):571-581. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. PMID: 28692774.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools. BMC Med Educ. 2017 Nov 06; 17(1):190. Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. PMID: 29110662.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Lupus Sci Med. 2017; 4(1):e000229. Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D. PMID: 29214037.
      View in: PubMed   Mentions:
    26. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol. 2017 01; 69(1):122-130. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. PMID: 27390168.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    27. In memoriam: Ephraim P. Engleman, MD, 1911-2015. Arthritis Rheumatol. 2015 Nov; 67(11):2795-6. Wofsy D. PMID: 26508466.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015; 2(1):e000089. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. PMID: 26023331.
      View in: PubMed   Mentions:
    29. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheumatol. 2015 May; 67(5):1144-6. Wofsy D, Diamond B, Houssiau FA. PMID: 25779381.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    30. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov; 74(11):2006-15. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. PMID: 24951103.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    31. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013 Jun; 65(6):1586-91. Wofsy D, Hillson JL, Diamond B. PMID: 23529285.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    32. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii66-8. Wofsy D. PMID: 23253930.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 Nov; 64(11):3660-5. Wofsy D, Hillson JL, Diamond B. PMID: 22806274.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    34. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17; 365(20):1886-95. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N. PMID: 22087680.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    35. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):846-54. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. PMID: 21285160.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    36. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. PMID: 21080348.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    37. Plagiarism on personal statements: a disturbing symptom of a broader trend. Ann Intern Med. 2010 Jul 20; 153(2):128-9. Papadakis MA, Wofsy D. PMID: 20643994.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5. Dall'Era M, Wofsy D. PMID: 20197774.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    39. Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3. Dall'Era M, Wofsy D. PMID: 20102681.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 Jan; 62(1):211-21. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. PMID: 20039429.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    41. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010 Jan; 49(1):128-40. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. PMID: 19933596.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    42. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. Esensten JH, Wofsy D, Bluestone JA. PMID: 19798031.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    43. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51. Dall'Era M, Wofsy D. PMID: 19491915.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    44. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May; 20(5):1103-12. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. PMID: 19369404.
      View in: PubMed   Mentions: 200     Fields:    Translation:Humans
    45. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009 Apr 01; 301(13):1367-72. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. PMID: 19336712.
      View in: PubMed   Mentions: 53     Fields:    
    46. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009 Mar 15; 61(3):370-7. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E. PMID: 19248127.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    47. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. PMID: 18050206.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCellsCTClinical Trials
    48. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007; 16(12):972-80. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. PMID: 18042591.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    49. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80. Dall'Era M, Wofsy D. PMID: 16896285.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Arthritis Rheum. 2006 Apr 15; 55(2):322-4. Daikh DI, Gillis J, Wofsy D. PMID: 16583382.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    51. Living in a different world. Arthritis Rheum. 2005 Feb; 52(2):395-401. Wofsy D. PMID: 15692996.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Block and tackle: CTLA4Ig takes on lupus. Lupus. 2005; 14(3):197-203. Davidson A, Diamond B, Wofsy D, Daikh D. PMID: 15807196.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    53. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. PMID: 12483729.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    54. Treatment of autoimmune diseases by inhibition of T-cell costimulation. Mod Rheumatol. 2002 Mar; 12(1):1-4. Wofsy D, Daikh DI. PMID: 24383824.
      View in: PubMed   Mentions:    Fields:    
    55. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum. 2001 Aug; 44(8):1730-5. Diamond B, Bluestone J, Wofsy D. PMID: 11508422.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    56. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 Mar 01; 166(5):2913-6. Daikh DI, Wofsy D. PMID: 11207238.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    57. Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets. Kidney Int. 2001 Feb; 59(2):565-78. Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V. PMID: 11168938.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    58. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan; 28(1):95-101. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. PMID: 11196549.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    59. Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol. 2001; 490:113-7. Daikh DI, Wofsy D. PMID: 11505969.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    60. The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. Immunology. 1999 Nov; 98(3):475-80. Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ. PMID: 10583610.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    61. Effects of anti-B7 monoclonal antibodies on humoral immune responses. J Autoimmun. 1999 Mar; 12(2):101-8. Daikh DI, Wofsy D. PMID: 10047430.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    62. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Transplant Proc. 1998 Dec; 30(8):4027-8. Daikh DI, Wofsy D. PMID: 9865285.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    63. Opportunities for future biological therapy in SLE. Baillieres Clin Rheumatol. 1998 Aug; 12(3):529-41. Wofsy D, Daikh DI. PMID: 9890111.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Clin Immunol Immunopathol. 1998 Apr; 87(1):23-32. Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. PMID: 9576007.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    65. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 01; 159(7):3104-8. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. PMID: 9317105.
      View in: PubMed   Mentions: 47     Fields:    Translation:Animals
    66. The CD28-B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol. 1997 Aug; 62(2):156-62. Daikh D, Wofsy D, Imboden JB. PMID: 9261329.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    67. Blind T-cell homeostasis in CD4-deficient mice. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 01; 11(4):334-40. Adleman LM, Wofsy D. PMID: 8601219.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    68. Treatment of murine lupus with CTLA4Ig. Science. 1994 Aug 26; 265(5176):1225-7. Finck BK, Linsley PS, Wofsy D. PMID: 7520604.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    69. Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol. 1994 Aug; 72(2):198-203. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. PMID: 8050193.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    70. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994 Aug; 94(2):585-91. Finck BK, Chan B, Wofsy D. PMID: 8040314.
      View in: PubMed   Mentions: 64     Fields:    Translation:Animals
    71. Recent advances in the treatment of rheumatic diseases: new approaches to immunotherapy. Ryumachi. 1994 Apr; 34(2):164-5. Wofsy D. PMID: 8202830.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    72. T-cell homeostasis: implications in HIV infection . J Acquir Immune Defic Syndr (1988). 1993 Feb; 6(2):144-52. Adleman LM, Wofsy D. PMID: 8094457.
      View in: PubMed   Mentions:
    73. Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunol Ser. 1993; 59:221-36. Wofsy D. PMID: 8096400.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    74. The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies. Clin Immunol Immunopathol. 1992 Dec; 65(3):234-41. Finck BK, Yung CM, Carteron NL, Wofsy D. PMID: 1360341.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    75. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol. 1992 Nov 01; 149(9):3083-8. Connolly K, Roubinian JR, Wofsy D. PMID: 1357036.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    76. Tumorigenesis mediated by an antigen receptor. Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8482-6. Jäck HM, Beck-Engeser G, Lee G, Wofsy D, Wabl M. PMID: 1528851.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    77. CD4 antibody therapy in systemic lupus erythematosus. Semin Immunol. 1990 Nov; 2(6):419-25. Wofsy D, Carteron NL. PMID: 2104279.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    78. F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice. Clin Immunol Immunopathol. 1990 Sep; 56(3):373-83. Carteron NL, Wofsy D, Schimenti C, Ermak TH. PMID: 1975226.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    79. Regulation of immunity by anti-T-cell antibodies. West J Med. 1990 Sep; 153(3):265-8. Wofsy D. PMID: 2219889.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    80. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol. 1990 Mar 01; 144(5):1753-8. Gordon C, Wofsy D. PMID: 2307839.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    81. Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. Lab Invest. 1989 Oct; 61(4):447-56. Ermak TH, Steger HJ, Wofsy D. PMID: 2529396.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    82. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989 Sep; 52(3):421-34. Gordon C, Ranges GE, Greenspan JS, Wofsy D. PMID: 2758698.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    83. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Clin Immunol Immunopathol. 1989 Aug; 52(2):190-201. Erlich KS, Wofsy D, Dix RD, Mills J. PMID: 2525439.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    84. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 01; 142(5):1470-5. Carteron NL, Schimenti CL, Wofsy D. PMID: 2521880.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    85. New therapies for the rheumatic diseases. Bull Rheum Dis. 1989; 38(4):1-8. Klippel JH, Strober S, Wofsy D. PMID: 2670022.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    86. Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease. J Autoimmun. 1988 Oct; 1(5):415-31. Wofsy D, Chiang NY, Greenspan JS, Ermak TH. PMID: 3267085.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    87. The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. J Autoimmun. 1988 Apr; 1(2):207-17. Wofsy D. PMID: 2978113.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    88. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol. 1988 Feb 01; 140(3):713-6. Carteron NL, Wofsy D, Seaman WE. PMID: 2448372.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    89. Treatment of autoimmune diseases with monoclonal antibodies. Prog Allergy. 1988; 45:106-20. Wofsy D. PMID: 3064092.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    90. Selective manipulation of the immune response in vivo by monoclonal antibodies. Annu Rev Med. 1988; 39:231-41. Seaman WE, Wofsy D. PMID: 3285774.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    91. New approaches to treating systemic lupus erythematosus. West J Med. 1987 Aug; 147(2):181-6. Wofsy D. PMID: 3310402.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    92. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice. Eur J Immunol. 1987 Jun; 17(6):809-14. Wofsy D, Chiang NY. PMID: 2954827.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    93. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987 May 15; 138(10):3247-53. Wofsy D, Seaman WE. PMID: 3106478.
      View in: PubMed   Mentions: 33     Fields:    Translation:Animals
    94. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation. 1986 Dec; 42(6):636-42. Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE. PMID: 2947360.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    95. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol. 1986 Dec 01; 137(11):3414-9. Gutstein NL, Wofsy D. PMID: 3097122.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    96. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15; 137(4):1127-32. Gutstein NL, Seaman WE, Scott JH, Wofsy D. PMID: 3090139.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    97. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol. 1986 Jun 15; 136(12):4554-60. Wofsy D. PMID: 3086436.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    98. Anti-Ly-1 antibody induces interleukin 2 release from T cells. J Immunol. 1986 Mar 01; 136(5):1734-7. Stanton T, Stevens TL, Ledbetter JA, Wofsy D. PMID: 3081630.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    99. Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4. Immunol Res. 1986; 5(2):97-105. Wofsy D, Seaman WE. PMID: 3093610.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    100. Strategies for treating autoimmune disease with monoclonal antibodies. West J Med. 1985 Dec; 143(6):804-9. Wofsy D. PMID: 3911593.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    101. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol. 1985 Oct; 135(4):2331-6. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. PMID: 3928743.
      View in: PubMed   Mentions: 53     Fields:    Translation:AnimalsCells
    102. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol. 1985 Sep; 135(3):1698-701. Wofsy D, Mayes DC, Woodcock J, Seaman WE. PMID: 3160776.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    103. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 01; 161(2):378-91. Wofsy D, Seaman WE. PMID: 3919141.
      View in: PubMed   Mentions: 114     Fields:    Translation:AnimalsCells
    104. Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985 Feb; 134(2):852-7. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. PMID: 3871218.
      View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
    105. [Not Available]. Immunol Today. 1984 Jul; 5(7):191-2. Wofsy D. PMID: 25289950.
      View in: PubMed   Mentions:    Fields:    
    106. Hormones, handedness, and autoimmunity. Immunol Today. 1984 Jun; 5(6):169-70. Wofsy D. PMID: 25289744.
      View in: PubMed   Mentions:    Fields:    
    107. The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens. J Immunol. 1984 Jun; 132(6):2686-9. Wofsy D, Hardy RR, Seaman WE. PMID: 6144707.
      View in: PubMed   Mentions: 37     Fields:    Translation:AnimalsCells
    108. Monocytosis in the BXSB model for systemic lupus erythematosus. J Exp Med. 1984 Feb 01; 159(2):629-34. Wofsy D, Kerger CE, Seaman WE. PMID: 6363600.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    109. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr; 130(4):1713-8. Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. PMID: 6187819.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    110. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. Clin Immunol Immunopathol. 1983 Mar; 26(3):361-9. Shear HL, Wofsy D, Talal N. PMID: 6872348.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCellsPHPublic Health
    111. Thymic influences on autoimmunity in MRL-lpr mice. Scand J Immunol. 1982 Jul; 16(1):51-8. Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N. PMID: 6981841.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    112. Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Arthritis Rheum. 1982 Jul; 25(7):838-42. Talal N, Dauphinee MJ, Wofsy D. PMID: 6285934.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    113. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol. 1981 Dec; 127(6):2483-7. Dauphinée MJ, Kipper SB, Wofsy D, Talal N. PMID: 6975325.
      View in: PubMed   Mentions: 54     Fields:    Translation:Animals
    114. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med. 1981 Nov 01; 154(5):1671-80. Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. PMID: 6975351.
      View in: PubMed   Mentions: 62     Fields:    Translation:AnimalsCells
    115. Interleukin-2 deficiency in murine systemic lupus erythematosus. Trans Assoc Am Physicians. 1981; 94:341-8. Wofsy D, Dauphinée MJ, Kipper SB, Talal N. PMID: 6979821.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    116. Culture-negative septic arthritis and bacterial endocarditis. Diagnosis by synovial biopsy. Arthritis Rheum. 1980 May; 23(5):605-7. Wofsy D. PMID: 6990934.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    117. Coccidioidomycosis of the thyroid. Ann Intern Med. 1979 Sep; 91(3):409-11. Loeb JM, Livermore BM, Wofsy D. PMID: 475170.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    David's Networks
    Concepts (376)
    Derived automatically from this person's publications.
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _